Q2 2025 |
10 |
$264M |
$0 |
$0 |
|
BBD, PCRX, DVA, NSSC, INMD
|
13F-HR |
8/11/2025, 08:25 PM |
Q1 2025 |
10 |
$254M |
+$47.8M |
-$1.98M |
+$45.8M |
PCRX, DVA, INMD, BBD, NSSC
|
13F-HR |
5/15/2025, 10:30 AM |
Q4 2024 |
8 |
$201M |
+$11.7M |
$0 |
+$11.7M |
INMD, PCRX, SIRI, BBD, NSSC
|
13F-HR |
2/14/2025, 09:57 AM |
Q3 2024 |
8 |
$198M |
+$67.7M |
-$89.8M |
-$22M |
INMD, BBD, NSSC, SIRI, PCRX
|
13F-HR |
11/14/2024, 01:10 PM |
Q2 2024 |
9 |
$216M |
+$76.5M |
-$5.21M |
+$71.3M |
DVA, INMD, PCRX, BBD, LSXMK
|
Restatement |
9/10/2024, 01:24 PM |
Q1 2024 |
9 |
$150M |
+$34.3M |
-$161K |
+$34.1M |
DVA, LSXMK, PCRX, INMD, NSSC
|
Restatement |
9/10/2024, 01:23 PM |
Q4 2023 |
8 |
$101M |
$0 |
$0 |
|
DVA, LSXMK, BBD, NSSC, AFYA
|
13F-HR |
2/14/2024, 09:53 AM |